...other was a partnership with antibody play Symphogen A/S...
...against up to six targets. The partnership with Symphogen...
...innovative science. What really highlights that is Symphogen...

...high-profile European biotech is now going out quietly as Servier is acquiring Danish mAb company Symphogen A/S...
...for $2.4 billion (see “Servier to Gain Shire’s Cancer Business” ). The deal gives Servier Symphogen’s...
...patients with metastatic colorectal cancer (see “Symphogen’s Sym004 Misses in Phase II for mCRC” ). Symphogen...

...ApS (Copenhagen, Denmark) and has held roles at Novo Nordisk A/S (CSE:NOVO B; NYSE:NVO) and Symphogen A/S...

...therapy Endocrine/ metabolic, hematology, neurology Cell Medica Ltd. $178.1 3/16/17 Off-the-shelf CAR-NKT cell therapies Cancer Symphogen A/S...

...Capital, North Sound Capital and Connecticut Innovations. Symphogen looking to raise $86M for antibody platform Symphogen A/S...
...support commercialization of the company's platform for generating therapeutic antibodies for cancer and other diseases. Symphogen...
...options, including spin-offs or a potential sale of the company. Sandi Wong, Staff Writer Applied Therapeutics Inc. IsoPlexis Corp. Symphogen A/S ArcherDx...

...Ltd. (Singapore) hired Ivan Horak as president of R&D. He joins the immunotherapy company from Symphogen A/S...

...CMO. He was chief development officer at PsiOxus Therapeutics Ltd. (Abingdon, U.K.). Cancer antibody company Symphogen A/S...

...presented by Symphogen A/S at AACR. A third was published in 2017 by CytoSite BioPharma Inc. Symphogen’s...
...signals from both tracers correlated with response to its PD-1 mAb Sym021 in mouse tumors. Symphogen...
...AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Regeneron Pharmaceuticals Inc. (NASDAQ:REGN), Tarrytown, N.Y. Stanford University, Stanford, Calif. Symphogen A/S...

...A) 12/12/16 ADC Therapeutics S.A. $435.0 10/23/17 CureVac AG $320.5 11/8/16 Immunocore Ltd. $320.0 7/16/15 Symphogen A/S...

...Durham, N.C.) to develop CAR T cell therapies for up to six targets and with Symphogen A/S...